Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
Completed · Phase 2
Conditions studied: Hepatitis C Virus Infection
In brief
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) Class C cirrhosis.
Key facts
- Study ID
- NCT02994056
- Run by
- Gilead Sciences
- People needed
- 32
- Starts
- 2017-01-23
- Expected to finish
- 2018-12-12
- Last updated by the study team
- 2020-03-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Tampa General Medical Group — Tampa, Florida, United States
- Northwestern Memorial Hospital; Clinical Research Unit — Chicago, Illinois, United States
- Digestive Disease Associates, PA — Catonsville, Maryland, United States
- Southern Therapy and Advanced Research LLC — Jackson, Mississippi, United States
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- American Research Corporation at Texas Liver Institute — San Antonio, Texas, United States
- Intermountain Liver Disease and Transplant Center — Murray, Utah, United States
- Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia — Richmond, Virginia, United States
- University of Washington/ Harborview Medical Center — Seattle, Washington, United States
- Hopital Henri Mondor — Créteil, France
- Hopital Paul Brousse — Villejuif, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.